NCAM1 and acute lymphoblastic leukemia: Since expression of CD56 (NCAM) has been observed in a significant proportion of cases of AML, ALL, MM and B-NHL and is associated with extramedullary involvement and poor prognosis, we have selected one case of aggressive CD56+ AML for in vivo inoculation in mice.